Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01476046
Other study ID # 110951
Secondary ID
Status Completed
Phase Phase 1
First received March 15, 2011
Last updated June 9, 2017
Start date March 8, 2011
Est. completion date June 17, 2012

Study information

Verified date June 2017
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of the study is to see how safe GSK1995057 is and how well it is tolerated after dosing. The study will also investigate how GSK1995057 is taken up, metabolised (chemically broken down), distributed through the body and excreted, and what some of the effects of the study drug are.


Description:

This study will be the first investigation of GSK1995057 in humans and is primarily designed to investigate safety and tolerability of single and repeat intravenously infused doses. The study will enrol healthy male subjects and healthy female subjects of non-child bearing potential and will also investigate immunogenicity, GSK1995057 distribution (pharmacokinetics), and potential impact on indicators of host immunity and normal immunological function. Safety, tolerability, immunogenicity, pharmacokinetic and pharmacodynamic data from this trial may facilitate further clinical investigations in healthy subjects dosed with GSK1995057 via the inhaled route, and ultimately clinical trials in patients with acute lung injury.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date June 17, 2012
Est. primary completion date June 17, 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Healthy as determined by a responsible and experienced physician.

- Male or female between 18 and 55 years of age inclusive

- A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, hysterectomy or bilateral oophorectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea and elevated FSH as per the local laboratory guidelines.

- Normal creatinine clearance values at screening

- Male subjects must agree to use one of the study specific contraception methods

- Body weight = 50 kg and BMI within the range 19 - 29.9 kg/m2 (inclusive).

- Normal lung function at screening.

- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

- Available to complete all study assessments.

- Able to read, comprehend and write English at a sufficient level to complete study elated materials.

Exclusion Criteria:

- A history of Hepatitis B, Hepatitis C or HIV infection and/or a positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening

- Current or chronic history of liver disease, or known hepatic or biliary abnormalities. (With the exception of known Gilbert's syndrome or asymptomatic gallstones).

- A positive pre-study drug/alcohol screen.

- Evidence of previous or active mycobacterium tuberculosis complex infection

- Recent history of and/or a positive test for Toxoplasma consistent with active oxoplasmosis infection.

- A positive test for influenza A/B taken within 7 days before dosing.

- Current evidence or history of an influenza-like illness.

- Corrected QT interval (QTcF) >450msec from ECG readings.

- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol and the following can be used as a guide: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.

- The subject is unwilling to abstain from alcohol consumption from 24 hr prior to dosing until discharge from the clinic, and for 24 hr prior to all other out-patient clinic visits.

- Subjects with a smoking history of >10 cigarettes per day in the last 3 months.

- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 90 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer) or exposure to more than four new chemical or biological entities within 12 months prior to the first dosing day.

- Subjects having received any type of vaccination within 3 weeks of the anticipated dosing start or are expected to be vaccinated within 3 weeks after the last dose.

- Current evidence of ongoing or acute infection, history of repeated or chronic significant infections or history of serious infection within three months of dosing.

- Subjects who have asthma or a history of asthma, COPD, other respiratory conditions or recurrent infections (a subject who suffered from childhood asthma but not as an adult may be included provided they fulfil other entry criteria).

- Subjects who have a known history of migraine headaches or are frequently suffering from other types of headaches which require medication (frequent defined as more than one headache in a fortnight).

- Use of prescription or non-prescription drugs (except simple analgesics), including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and sponsors Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.

- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy including severe allergic reaction, angio-edema or anaphylaxis that, in the opinion of the investigator or sponsors Medical Monitor, contraindicates their participation.

- History of malignancy, except for adequately treated non-invasive cancer of the skin (basal or squamous cell) or cervical carcinoma in situ (>2 yrs prior to dosing).

- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 3 month or 90 day period.

- Subject is unable to refrain from travelling to countries with a high prevalence of TB or other areas of prevalent infectious disease as judged by the investigator or the sponsors medical monitor from the start of screening until the final follow-up visit.

- Subject is mentally or legally incapacitated.

Study Design


Intervention

Drug:
GSK1995057 single dose
Single intravenous dose
Placebo
Single intravenous dose

Locations

Country Name City State
United Kingdom GSK Investigational Site Harrow Middlesex

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurance of adverse events. Number and type of adverse events recorded during study. From start of screening until 84 days after completion of single dose (Part A subjects) or first dose (Part B subjects).
Primary Change from baseline in blood pressure. Systolic and diastolic blood pressure values before and after dosing completion. From start of screening until 28 days after completion of single or repeat dosing.
Primary Change from baseline in heart rate. Heart rate before and after dosing completion. From start of screening until 28 days after completion of single or repeat dosing.
Primary Change from baseline in respiration rate. Respiration rate before and after dosing completion. From start of screening until 28 days after completion of single or repeat dosing.
Primary Change from baseline in body temperature. Body temperature before and after dosing completion. From start of screening until 28 days after completion of single or repeat dosing.
Primary Change from baseline in heart function. Holter recording. For 24hrs during screening, then for 1 hour before dosing to 24 hours after dosing starts (in Part A subjects only, except for cohort 7).
Primary Change from baseline in heart function Lead II cardiac telemetry. From 1 hour before dosing to 12 hours after dosing starts for each dose.
Primary Change from baseline in heart function. 12-lead ECG recording. From start of screening until 28 days after completion of single or repeat dosing.
Primary Change from baseline in lung function. FEV1 and FVC measurements. From start of screening until 28 days after completion of single or repeat dosing.
Primary Change from baseline in laboratory safety data. Clinical chemistry, haematology and routine urinalysis. From start of screening until 28 days after completion of single or repeat dosing.
Secondary Plasma pharmacokinetics of GSK1995057 Levels of GSK1995057 in blood samples. From the first day of dosing until 48 hours after the completion of dosing.
Secondary Urine pharmacokinetics of GSK1995057 Levels of GSK1995057 in urine samples from cohort 6 subjects only. From 1 hour before the only dose until 48 hours after the dose.
Secondary Bronchoalveolar lavage fluid (BALF) (saline flushed into and then collected from a lung) pharmacokinetics. Levels of GSK1995057 in BALF from cohort 7 subjects only. At 2 hrs after the completion of the only dose.
Secondary Effect of GSK1995057 on host immunity and immunological function Levels of pharmacodynamic and immune function biomarkers in blood samples. From the day before dosing starts to 28 days after dosing completion.
Secondary Effects of GSK1995057 on host immunity and immunological function Levels of pharmacodynamic and immune function biomarkers in BALF from cohort 7 subjects only. At 2 hrs after the completion of the only dose.
Secondary Immunogenic effect of GSK1995057 Levels of anti-GSK1995057 antibodies in blood samples From the start of screening (cohorts 1-4 only) or from the day before the start of dosing until 84 days after the completion of single or repeat dosing.
See also
  Status Clinical Trial Phase
Completed NCT01443845 - Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Phase 4
Withdrawn NCT00844935 - Electrocardiographic Autonomic Function Measures in Mechanically Ventilated Patients N/A
Completed NCT01395849 - Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) N/A
Completed NCT03557645 - Ventilator Hyperinflation and Hemodynamics N/A
Completed NCT03281876 - A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response. Phase 2
Completed NCT01395862 - Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol) N/A
Completed NCT01587807 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057 Phase 1
Completed NCT00835003 - Timing of Planned Caesarean Section and Morbidity of the Newborn N/A
Completed NCT03443427 - A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine Phase 2
Completed NCT01360398 - Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly N/A
Completed NCT03201211 - A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults Phase 1
Completed NCT02075541 - A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction. Phase 2
Completed NCT00455767 - Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients Phase 2
Withdrawn NCT01505556 - Proprioceptive Postural Control and Diaphragm Paresis
Completed NCT01505582 - Inspiratory Muscle Training and Low Back Pain N/A
Completed NCT02322671 - Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects Phase 1
Completed NCT01818024 - A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers Phase 1
Recruiting NCT02316379 - Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration Phase 1/Phase 2
Completed NCT01516437 - A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD N/A
Recruiting NCT02272049 - Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults Phase 1/Phase 2